Avastin doesn't blind people, people blind people

American Journal of Ophthalmology

Volumn 153, Issue 2, 2012, Pages

  Gonzalez, Serafin ^a   Rosenfeld, Philip J ^a   Stewart, Michael W ^b   Brown, Jennifer ^b   Murphy, Steven P ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ARTICLE; ASEPSIS; DRUG CONTAMINATION; DRUG FORMULATION; DRUG SYNTHESIS; ENDOPHTHALMITIS; EPIDEMIC; HUMAN; MICROBIAL CONTAMINATION; PRIORITY JOURNAL; STANDARDIZATION; SYRINGE; VISUAL IMPAIRMENT;

EID: 84862914622     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2011.11.023     Document Type: Article

References (36)

1. R.A. Goldberg, H.W. Flynn, R.F. Isom, D. Miller, and S. Gonzalez An outbreak of Streptococcus endophthalmitis after intravitreal injection of bevacizumab Am J Ophthalmol 153 2 2012 204 208
2. United States Food and Drug Administration FDA alerts health care professionals of infection risk from repackaged Avastin intravitreal injections August 30, 2011 http://www.fda.gov/Drugs/DrugSafety/ucm270296.htm Accessed October 15, 2011
3. A. Pollack Doctors grow wary of Avastin for eye treatment October 4, 2011 http://prescriptions.blogs.nytimes.com/2011/10/04/doctors-grow-wary-of-avastin- for-eye-treatment/?ref=andrewpollack Accessed October 15, 2011
4. AAO update: VA reinstates use of Avastin October 31, 2011 http://www.mdeye.org/community/orca/topic/AAO-Update:-VA-Reinstates-Use-of- Avastin.htm Accessed November 13, 2011
5. R.J. Brechner, P.J. Rosenfeld, J.D. Babish, S. Caplan Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service part B claims file Am J Ophthalmol 151 5 2011 887e1 895e1
6. D.F. Martin, M.G. Maguire, G.S. Ying, J.E. Grunwald, S.L. Fine, G.J. Jaffe Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 20 2011 1897 1908
7. Department of Ophthalmology and Vision Sciences, Faculty of Medicine, University of Toronto Severe intraocular inflammation/endophthalmitis following off-label treatment with intravitreal bevacizumab 2009 http:// ophthalmologyrounds.ca/modules/contentManager/upload/document/alwaysOnLine/ ScientificUpdate-en.pdf Accessed November 13, 2011
8. M. Fielden, B. Nelson, A. Kherani Acute intraocular inflammation following intravitreal injection of bevacizumaba large cluster of cases Acta Ophthalmologica 89 8 2011 e664 e665
9. J. Corbett Dooren Update: Roche unit failed to follow safety procedures, FDA says Wall Street Journal November 4, 2011 http://online.wsj.com/article/BT- CO-20111104-717759.html Accessed November 13, 2011
10. T. Sato, K. Emi, T. Ikeda Severe intraocular inflammation after intravitreal injection of bevacizumab Ophthalmology 117 3 2010 512 516 516e1e2
11. K. Yamashiro, A. Tsujikawa, K. Miyamoto Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch Retina 30 3 2010 485 490
12. C. Neumann Verblffende Wirkung Der Spiegel 40 2008 140 141 http://wissen.spiegel.de/wissen/image/show.html?did=60666870&aref=image038/ 2008/09/27/ROSP200804001400141.PDF&thumb=false Accessed November 13, 2011
13. X. Sun, X. Xu, X. Zhang Counterfeit bevacizumab and endophthalmitis N Engl J Med 365 4 2011 378 379 author reply 379
14. S.H. Lee, S.J. Woo, K.H. Park Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab Eye (Lond) 24 2 2010 226 232
15. M.Y. Kahook, L. Liu, P. Ruzycki High-molecular-weight aggregates in repackaged bevacizumab Retina 30 6 2010 887 892
16. L. Liu, D.A. Ammar, L.A. Ross, N. Mandava, M.Y. Kahook, J.F. Carpenter Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling Invest Ophthalmol Vis Sci 52 2 2011 1023 1034
17. R. Civen, D.J. Vugia, R. Alexander Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy Clin Infect Dis 43 7 2006 831 837 (Pubitemid 44435508)
18. Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacyUnited States, JulyNovember 2002 MMWR Morbid Mortal Wkly Rep 51 49 2002 1109 1112 www.cdc.gov/mmwr/preview/mmwrhtml/mm5149a1.htm Accessed October 15, 2011
19. National Coordinating Committee on Large Volume Parenterals Recommended methods for compounding intravenous admixtures in hospitals Am J Hosp Pharm 32 1975 261 270
20. American Society of Health-System Pharmacists ASHP guidelines on quality assurance for pharmacy-prepared sterile products Am J Health Syst Pharm 57 2000 1150 1169
21. st ed. 2003 The United States Pharmacopeial Convention Rockville, MD 2417 2429
22. J.P. Santell, R.F. Kamalich National survey of quality assurance activities for pharmacy prepared sterile products in hospitals and home infusion facilities1995 Am J Health Syst Pharm 53 1996 2591 2605 (Pubitemid 26365326)
23. United States Food and Drug Administration Report: limited FDA survey of compounded drug products June 18, 2009 www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm155725.htm Accessed October 15, 2011
24. A.M. Morris, M. Aisha, P.J. Schneider, C.A. Pedersen, J.M. Mirtallo National survey of quality assurance activities for pharmacy-compounded sterile preparations Am J Health Syst Pharm 60 2003 2567 2576 (Pubitemid 44712858)
25. L.R. Harteker Federal court strikes down compounding regulations Am J Health System Pharm 58 2001 638 643 (Pubitemid 32319358)
26. E.S. Kastango, B.D. Bradshaw USP chapter 797: establishing a practice standard for compounding sterile preparations in pharmacy Am J Health Syst Pharm 61 2004 1928 1938 (Pubitemid 39481348)
27. th rev. The National Formulary 22nd ed. 2004 The United States Pharmacopeial Convention Rockville, MD 2350 2370
28. M. Sanborn It's Time to Clean Up <797> Hosp Pharm 41 2006 1018 1019
29. M. Thomas, M.D. Sanborn, R. Couldry I.V. admixture contamination rates: traditional practice site versus a class 1000 cleanroom Am J Health Syst Pharm 62 2005 2386 2392 (Pubitemid 41705192)
30. United States Pharmacopeia Pharmaceutical compounding: sterile preparations (general information chapter 797) Revision Bulletin, The United States Pharmacopeia 2008 The United States Pharmacopeial Convention Rockville, MD 1 61
31. S.J. Bakri, M.R. Snyder, J.S. Pulido, C.A. McCannel, W.T. Weiss, R.J. Singh Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing Retina 26 5 2006 519 522 (Pubitemid 44620392)
32. th ed. 2008 The United States Pharmacopeia Convention Rockville, MD 85 91
33. M.R. Held, E.M. Begier, D.S. Beardsley Life-threatening sepsis caused by Burkholderia cepacia from contaminated intravenous flush solutions prepared by a compounding pharmacy in another state Pediatrics 118 1 2006 e212 e215 (Pubitemid 46071138)
34. R.H. Sunenshine, E.T. Tan, D.M. Terashita A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy Clin Infect Dis 45 5 2007 527 533 (Pubitemid 47328631)
35. M.D. Gershman, D.J. Kennedy, J. Noble-Wang Multistate outbreak of Pseudomonas fluorescens bloodstream infection after exposure to contaminated heparinized saline flush prepared by a compounding pharmacy Clin Infect Dis 47 11 2008 1372 1379
36. L.L. Maragakis, R. Chaiwarith, A. Srinivasan Sphingomonas paucimobilis bloodstream infections associated with contaminated intravenous fentanyl Emerg Infect Dis 15 1 2009 12 18